The pan-PI3K inhibitor GDC-0941 activates canonical WNT signaling to confer resistance in TNBC cells: Resistance reversal with WNT inhibitor

Oncotarget

Volumn 6, Issue 13, 2015, Pages 11061-11073

  Tzeng, Huey En ^a,c,d,e   Yang, Lixin ^a   Chen, Kemin ^a   Wang, Yafan ^a   Liu, Yun Ru ^b   Pan, Shiow Lin ^b   Gaur, Shikha ^a   Hu, Shuya ^a   Yen, Yun ^a,b  

^a CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^b TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^c CHINA MEDICAL UNIVERSITY   (Taiwan)

^d TAICHUNG VETERANS GENERAL HOSPITAL   (Taiwan)

^e CHINA MEDICAL UNIVERSITY   (Taiwan)

Author keywords

Drug resistance; Pan PI3K inhibitor; PI3K AKT mTOR pathway; Triple negative breast cancer; WNT beta catenin pathway

Indexed keywords

BETA CATENIN; LGK 974; MAMMALIAN TARGET OF RAPAMYCIN; PHOSPHATIDYLINOSITOL 3 KINASE; PICTILISIB; PROTEIN INHIBITOR; PROTEIN KINASE B; UNCLASSIFIED DRUG; WNT PROTEIN; 2-(1H-INDAZOL-4-YL)-6-(4-METHANESULFONYLPIPERAZIN-1-YLMETHYL)-4-MORPHOLIN-4-YLTHIENO(3,2-D)PYRIMIDINE; INDAZOLE DERIVATIVE; LGK974; MESSENGER RNA; MTOR PROTEIN, HUMAN; PYRAZINE DERIVATIVE; PYRIDINE DERIVATIVE; SULFONAMIDE; TARGET OF RAPAMYCIN KINASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL LINE; CANCER INHIBITION; CANCER RESISTANCE; CELL INTERACTION; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; DRUG POTENTIATION; ENZYME ACTIVITY; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; SIGNAL TRANSDUCTION; TRIPLE NEGATIVE BREAST CANCER; TUMOR GROWTH; ANIMAL; ANTAGONISTS AND INHIBITORS; APOPTOSIS; CELL PROLIFERATION; DRUG EFFECTS; DRUG RESISTANCE; DRUG SCREENING; FLUORESCENT ANTIBODY TECHNIQUE; GENETICS; METABOLISM; NUDE MOUSE; PATHOLOGY; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TRIPLE NEGATIVE BREAST NEOPLASMS; TUMOR CELL CULTURE; WESTERN BLOTTING;

ANIMALS; APOPTOSIS; BETA CATENIN; BLOTTING, WESTERN; CELL PROLIFERATION; DRUG RESISTANCE, NEOPLASM; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE; HUMANS; INDAZOLES; MICE; MICE, NUDE; PHOSPHATIDYLINOSITOL 3-KINASES; PROTO-ONCOGENE PROTEINS C-AKT; PYRAZINES; PYRIDINES; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SULFONAMIDES; TOR SERINE-THREONINE KINASES; TRIPLE NEGATIVE BREAST NEOPLASMS; TUMOR CELLS, CULTURED; WNT PROTEINS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84929645862     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.3568     Document Type: Article

References (39)

1. Dent R, Trudeau M, Pritchard KI, Hanna WM, Kahn HK, Sawka CA, Lickley LA, Rawlinson E, Sun P and Narod SA. Triple-negative breast cancer: clinical features and patterns of recurrence. Clinical cancer research : an official journal of the American Association for Cancer Research. 2007; 13(15 Pt 1):4429-4434.
2. Liedtke C, Mazouni C, Hess KR, Andre F, Tordai A, Mejia JA, Symmans WF, Gonzalez-Angulo AM, Hennessy B, Green M, Cristofanilli M, Hortobagyi GN and Pusztai L. Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J Clin Oncol. 2008; 26(8):1275-1281.
3. Lin NU, Claus E, Sohl J, Razzak AR, Arnaout A and Winer EP. Sites of distant recurrence and clinical outcomes in patients with metastatic triple-negative breast cancer: high incidence of central nervous system metastases. Cancer. 2008; 113(10):2638-2645.
4. Lehmann BD, Bauer JA, Chen X, Sanders ME, Chakravarthy AB, Shyr Y and Pietenpol JA. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest. 2011; 121(7):2750-2767.
5. Mayer IA, Abramson VG, Lehmann BD and Pietenpol JA. New strategies for triple-negative breast cancer-- deciphering the heterogeneity. Clinical cancer research :an official journal of the American Association for Cancer Research. 2014; 20(4):782-790.
6. Ibrahim YH, Garcia-Garcia C, Serra V, He L, Torres-Lockhart K, Prat A, Anton P, Cozar P, Guzman M, Grueso J, Rodriguez O, Calvo MT, Aura C, Diez O, Rubio IT, Perez J, et al. PI3K inhibition impairs BRCA1/2 expression and sensitizes BRCA-proficient triple-negative breast cancer to PARP inhibition. Cancer Discov. 2012; 2(11):1036-1047.
7. Najdi R, Holcombe RF and Waterman ML. Wnt signaling and colon carcinogenesis: beyond APC. J Carcinog. 2011; 10:5.
8. Su HY, Lai HC, Lin YW, Liu CY, Chen CK, Chou YC, Lin SP, Lin WC, Lee HY and Yu MH. Epigenetic silencing of SFRP5 is related to malignant phenotype and chemoresistance of ovarian cancer through Wnt signaling pathway. Int J Cancer. 2010; 127(3):555-567.
9. Khramtsov AI, Khramtsova GF, Tretiakova M, Huo D, Olopade OI and Goss KH. Wnt/beta-catenin pathway activation is enriched in basal-like breast cancers and predicts poor outcome. The American journal of pathology. 2010; 176(6):2911-2920.
10. Zhang J, Li Y, Liu Q, Lu W and Bu G. Wnt signaling activation and mammary gland hyperplasia in MMTVLRP6 transgenic mice: implication for breast cancer tumorigenesis. Oncogene. 2010; 29(4):539-549.
11. Yang L, Perez AA, Fujie S, Warden C, Li J, Wang Y, Yung B, Chen YR, Liu X, Zhang H, Zheng S, Liu Z, Ann D and Yen Y. Wnt modulates MCL1 to control cell survival in triple negative breast cancer. BMC Cancer. 2014; 14:124.
12. MacDonald BT, Tamai K and He X. Wnt/beta-catenin signaling: components, mechanisms, and diseases. Dev Cell. 2009; 17(1):9-26.
13. Geyer FC, Lacroix-Triki M, Savage K, Arnedos M, Lambros MB, MacKay A, Natrajan R and Reis-Filho JS. beta-Catenin pathway activation in breast cancer is associated with triple-negative phenotype but not with CTNNB1 mutation. Mod Pathol. 2011; 24(2):209-231.
14. Yang L, Wu X, Wang Y, Zhang K, Wu J, Yuan YC, Deng X, Chen L, Kim CC, Lau S, Somlo G and Yen Y. FZD7 has a critical role in cell proliferation in triple negative breast cancer. Oncogene. 2011; 30(43):4437-4446.
15. Lindvall C, Zylstra CR, Evans N, West RA, Dykema K, Furge KA and Williams BO. The Wnt co-receptor Lrp6 is required for normal mouse mammary gland development. PLoS One. 2009; 4(6):e5813.
16. Inoki K, Ouyang H, Zhu T, Lindvall C, Wang Y, Zhang X, Yang Q, Bennett C, Harada Y, Stankunas K, Wang CY, He X, MacDougald OA, You M, Williams BO and Guan KL. TSC2 integrates Wnt and energy signals via a coordinated phosphorylation by AMPK and GSK3 to regulate cell growth. Cell. 2006; 126(5):955-968.
17. Tenbaum SP, Ordonez-Moran P, Puig I, Chicote I, Arques O, Landolfi S, Fernandez Y, Herance JR, Gispert JD, Mendizabal L, Aguilar S, Ramon y Cajal S, Schwartz S, Jr., Vivancos A, Espin E, Rojas S, et al. beta-catenin confers resistance to PI3K and AKT inhibitors and subverts FOXO3a to promote metastasis in colon cancer. Nature medicine. 2012; 18(6):892-901.
18. Pez F, Lopez A, Kim M, Wands JR, Caron de Fromentel C and Merle P. Wnt signaling and hepatocarcinogenesis:molecular targets for the development of innovative anticancer drugs. Journal of hepatology. 2013; 59(5):1107-1117.
19. Clevers H. Wnt/beta-catenin signaling in development and disease. Cell. 2006; 127(3):469-480.
20. Liu J, Pan S, Hsieh MH, Ng N, Sun F, Wang T, Kasibhatla S, Schuller AG, Li AG, Cheng D, Li J, Tompkins C, Pferdekamper A, Steffy A, Cheng J, Kowal C, et al. Targeting Wnt-driven cancer through the inhibition of Porcupine by LGK974. Proc Natl Acad Sci U S A. 2013; 110(50):20224-20229.
21. Beagle B and Fruman DA. A lipid kinase cousin cooperates to promote cancer. Cancer cell. 2011; 19(6):693-695.
22. Graupera M and Potente M. Regulation of angiogenesis by PI3K signaling networks. Experimental cell research. 2013; 319(9):1348-1355.
23. Liu P, Cheng H, Roberts TM and Zhao JJ. Targeting the phosphoinositide 3-kinase pathway in cancer. Nature reviews Drug discovery. 2009; 8(8):627-644.
24. Fruman DA and Rommel C. PI3K and cancer: lessons, challenges and opportunities. Nature reviews Drug discovery. 2014; 13(2):140-156.
25. Foulkes WD, Smith IE and Reis-Filho JS. Triple-negative breast cancer. The New England journal of medicine. 2010; 363(20):1938-1948.
26. Carey LA, Dees EC, Sawyer L, Gatti L, Moore DT, Collichio F, Ollila DW, Sartor CI, Graham ML and Perou CM. The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes. Clinical cancer research : an official journal of the American Association for Cancer Research. 2007; 13(8):2329-2334.
27. Turner NC and Reis-Filho JS. Tackling the diversity of triple-negative breast cancer. Clinical cancer research : an official journal of the American Association for Cancer Research. 2013; 19(23):6380-6388.
28. De P, Sun Y, Carlson JH, Friedman LS, Leyland-Jones BR and Dey N. Doubling down on the PI3K-AKT-mTOR pathway enhances the antitumor efficacy of PARP inhibitor in triple negative breast cancer model beyond BRCA-ness. Neoplasia (New York, NY). 2014; 16(1):43-72.
29. Lehmann BD, Bauer JA, Schafer JM, Pendleton CS, Tang L, Johnson KC, Chen X, Balko JM, Gomez H, Arteaga CL, Mills GB, Sanders ME and Pietenpol JA. PIK3CA mutations in androgen receptor-positive triple negative breast cancer confer sensitivity to the combination of PI3K and androgen receptor inhibitors. Breast cancer research :BCR. 2014; 16(4):406.
30. Tao JJ, Castel P, Radosevic-Robin N, Elkabets M, Auricchio N, Aceto N, Weitsman G, Barber P, Vojnovic B, Ellis H, Morse N, Viola-Villegas NT, Bosch A, Juric D, Hazra S, Singh S, et al. Antagonism of EGFR and HER3 enhances the response to inhibitors of the PI3K-Akt pathway in triple-negative breast cancer. Science signaling. 2014; 7(318):ra29.
31. Anastas JN and Moon RT. WNT signalling pathways as therapeutic targets in cancer. Nature reviews Cancer. 2013; 13(1):11-26.
32. Chilosi M, Poletti V, Zamo A, Lestani M, Montagna L, Piccoli P, Pedron S, Bertaso M, Scarpa A, Murer B, Cancellieri A, Maestro R, Semenzato G and Doglioni C. Aberrant Wnt/beta-catenin pathway activation in idiopathic pulmonary fibrosis. The American journal of pathology. 2003; 162(5):1495-1502.
33. Inestrosa NC, Montecinos-Oliva C and Fuenzalida M. Wnt signaling: role in Alzheimer disease and schizophrenia. Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology. 2012; 7(4):788-807.
34. Schinner S. Wnt-signalling and the metabolic syndrome. Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme. 2009; 41(2):159-163.
35. Kahn M. Can we safely target the WNT pathway? Nature reviews Drug discovery. 2014; 13(7):513-532.
36. Groden J, Thliveris A, Samowitz W, Carlson M, Gelbert L, Albertsen H, Joslyn G, Stevens J, Spirio L, Robertson M and et al. Identification and characterization of the familial adenomatous polyposis coli gene. Cell. 1991; 66(3):589-600.
37. Kinzler KW, Nilbert MC, Su LK, Vogelstein B, Bryan TM, Levy DB, Smith KJ, Preisinger AC, Hedge P, McKechnie D and et al. Identification of FAP locus genes from chromosome 5q21. Science (New York, NY). 1991; 253(5020):661-665.
38. Herr P, Hausmann G and Basler K. WNT secretion and signalling in human disease. Trends in molecular medicine. 2012; 18(8):483-493.
39. Suzuki H, Watkins DN, Jair KW, Schuebel KE, Markowitz SD, Chen WD, Pretlow TP, Yang B, Akiyama Y, Van Engeland M, Toyota M, Tokino T, Hinoda Y, Imai K, Herman JG and Baylin SB. Epigenetic inactivation of SFRP genes allows constitutive WNT signaling in colorectal cancer. Nature genetics. 2004; 36(4):417-422.